A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Summary
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Part A Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator. 4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Exclusion Criteria: 1. Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies. 2. Radiothera…
Interventions
- DrugNXP900
NXP900 is an orally administered SRC/YES1 kinase inhibitor
Locations (12)
- Mayo ClinicPhoenix, Arizona
- Sarah Cannon Research Institute at HealthONEDenver, Colorado
- Mayo ClinicJacksonville, Florida
- University of ChicagoChicago, Illinois
- Mayo Clinic RochesterRochester, Minnesota
- Oregon Health and Science UniversityPortland, Oregon